PAVmed (PAVM)
(Delayed Data from NSDQ)
$1.77 USD
-0.08 (-4.32%)
Updated Apr 25, 2024 03:59 PM ET
After-Market: $1.77 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth C Momentum F VGM
Income Statements
Fiscal Year end for PAVmed Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 0 | 1 | 0 | 0 |
Cost Of Goods | 6 | 4 | 1 | 0 | 0 |
Gross Profit | -4 | -3 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 65 | 88 | 54 | 23 | 14 |
Income After Depreciation & Amortization | -69 | -91 | -54 | -23 | -14 |
Non-Operating Income | -10 | -11 | -2 | -12 | -3 |
Interest Expense | 1 | 1 | 0 | 0 | 0 |
Pretax Income | -79 | -103 | -56 | -36 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -15 | -14 | -6 | -2 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -79 | -103 | -56 | -36 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -64 | -89 | -50 | -34 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -66 | -88 | -54 | -23 | -14 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -69 | -91 | -54 | -23 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.23 | 5.94 | 5.17 | 3.16 | 2.01 |
Diluted EPS Before Non-Recurring Items | -7.32 | -9.15 | -6.45 | -6.45 | -5.85 |
Diluted Net EPS (GAAP) | -9.16 | -14.99 | -9.75 | -10.94 | -8.25 |
Fiscal Year end for PAVmed Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.05 | 0.79 | 0.17 | 0.45 |
Cost Of Goods | NA | 1.61 | 1.78 | 1.69 | 1.35 |
Gross Profit | NA | -0.56 | -0.99 | -1.52 | -0.90 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 15.83 | 14.54 | 14.97 | 19.51 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -16.39 | -15.53 | -16.49 | -20.41 |
Non-Operating Income | NA | -1.01 | -6.06 | -1.18 | -1.63 |
Interest Expense | NA | 0.02 | 0.16 | 0.23 | 0.18 |
Pretax Income | NA | -17.41 | -21.75 | -17.89 | -22.21 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -3.37 | -4.08 | -3.36 | -4.28 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -17.41 | -21.75 | -17.89 | -22.21 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -14.04 | -17.67 | -14.54 | -17.93 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 8.01 | 7.47 | 6.96 | 6.48 |
Diluted EPS Before Non-Recurring Items | NA | -1.57 | -1.65 | -1.35 | -1.50 |
Diluted Net EPS (GAAP) | NA | -1.96 | -2.40 | -2.10 | -2.70 |